Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > New Photosensitizers from Mushrooms
View:
Post by Eoganacht on Jan 21, 2022 11:33am

New Photosensitizers from Mushrooms

Austrian, Swiss and Dutch scientists claim to have discoved a natural substance derived from mushrooms that is as potent a photosensitizer as TLD1433. It's noteworthy that they chose TLD1433 as the standard with which to compare these new photosensitizers. The full article is here.:

Targeted isolation of photoactive pigments from mushrooms yielded a highly potent new photosensitizer: 7,7′-biphyscion

Abstract
 
Pigments of fungi are a fertile ground of inspiration: they spread across various chemical backbones, absorption ranges, and bioactivities. However, basidiomycetes with strikingly colored fruiting bodies have never been explored as agents for photodynamic therapy (PDT), even though known photoactive compound classes (e.g., anthraquinones or alkaloids) are used as chemotaxonomic markers. In this study, we tested the hypothesis that the dyes of skin-heads (dermocyboid Cortinarii) can produce singlet oxygen under irradiation and thus are natural photosensitizers. Three photosensitizers based on anthraquinone structures were isolated and photopharmaceutical tests were conducted. For one of the three, i.e., (–)-7,7′-biphyscion (1), a promising photoyield and photocytotoxicity of EC50 = 0.064 µM against cancer cells (A549) was found under blue light irradiation (λexc = 468 nm, 9.3 J/cm2). The results of molecular biological methods, e.g., a viability assay and a cell cycle analysis, demonstrated the harmlessness of 1 in the dark and highlighted the apoptosis-inducing PDT potential under blue light irradiation. These results demonstrate for the first time that pigments of dermocyboid Cortinarii possess a so far undescribed activity, i.e., photoactivity, with significant potential for the field of PDT. The dimeric anthraquinone (–)-7,7′-biphyscion (1) was identified as a promising natural photosensitizer.
.
.
.
....With these results, 1 is one of the most potent AQ-based PS so far known: With its average EC50, BL of approx. 0.05 µM 1 exceeds the photocytotoxicity of the reported monomeric AQs rubiadin (EC50, MCF7 = 74 µM) and soranjidiol (EC50, MCF7 = 37 µM)31 by more than 1300 fold. Thus, 1 represents a natural compound with a true potential as PDT hit structure. Furthermore, 1 demonstrated in vitro activities not inferior to those of transition metal complexes already used in clinical trials (i.e., Ru(II) polypyridiyl complex TLD1433 with an EC50 of 51 nM against cells of the U87 human glioblastoma cell line, activated by green light (530 nm, 45 J/cm2))32,33. Finally, the apoptosis-inducing character of 1 under irradiation rendered this new natural photosensitizer highly promising.
Comment by fredgoodwinson on Jan 21, 2022 11:47am
Do cancer cells have a preferential uptake of fungi pigments?
Comment by fredgoodwinson on Jan 21, 2022 11:56am
Just saying since the use glioblastoma as an example .They still face the challenges of the blood/brain barrier and getting their drug to selectively accumulate in tumour.
Comment by fredgoodwinson on Jan 21, 2022 12:18pm
Could it be lit up by x-ray?
Comment by 99942Apophis on Jan 21, 2022 12:32pm
fredgoodwinson wrote  Do cancer cells have a preferential uptake of fungi pigments? Hi Fred, I belong to a mushroom hunting group and within that group 2 people swear they had cancer and went through radiation treatment, they heard about several different shrooms that would halt cancers advance and put it into a suspended state. They consume those dried capsules varieties daily and both ...more  
Comment by Gooseybear on Jan 21, 2022 12:49pm
I'm glad you said alive. 
Comment by winr88 on Jan 21, 2022 3:35pm
Do turkey tail mushrooms benefit health? Cancer and immunity Gut health Risks How to use Summary Turkey tail mushrooms are multicolored fungi that grow on tree trunks and fallen trees in wooded areas. They are plentiful in various parts of the world, including the United States. These mushrooms have a disc-like shape ...more  
Comment by 99942Apophis on Jan 21, 2022 4:02pm
Yes winr88 Turkey tail mushrooms do have those claims however I would not recommend digesting until they have gone through a clinical study. There are many other polypore mushrooms that resemble the Turkey tail and if you are purchasing there are no guarantees the person picked the correct Turkey Tail. Learn what each mushroom is by its 8 points of identification and pick your own supply. Claims ...more  
Comment by Mikee3003 on Jan 21, 2022 5:14pm
Hi All, If anyone is interested in mushrooms/fungi I would highly recommend the Netflix documentary "Fantastic Fungi" I've actually watched it twice. Mikee
Comment by Eoganacht on Jan 21, 2022 1:04pm
Hi Fred. One of the compounds they studied had a selectivity index of 39 but it seems they are talking about the ratio of dark toxicity to irradiated toxicity not preferential uptake. In other papers I have read about photodynamic therapy selectivity index was related to preferential uptake by the targeted tissue. Could be this is another "point and shoot" photosensitizer, where they ...more  
Comment by 99942Apophis on Jan 21, 2022 1:46pm
In your understanding would either Eoganacht or Fredgoodwinson think that their current research investigation into Fungi be years away from a PH1 clinical study or perhaps a decades? Eoganacht wrote Hi Fred. One of the compounds they studied had a selectivity index of 39 but it seems they are talking about the ratio of dark toxicity to irradiated toxicity not preferential uptake. In other ...more  
Comment by fredgoodwinson on Jan 21, 2022 2:03pm
Eoganacht`s research always welcome and no room for complacency but yes 99942 essentially agree. There is a long road ahead of them that TLT has already travelled and no guarantee of success at the end of it.
Comment by 99942Apophis on Jan 21, 2022 12:18pm
Good find Eoganacht  The genus Cortinarius is one of the most diverse genera of mushrooms, with around 2000 species described worldwide (Garnica et al., 2005). Already, more than 100 species are known from Australia (May et al., 2009) and recent taxonomic research on the genus has continued to distinguish novel species (Gasparini and Soop, 2008;Jones and May, 2008). Dermocybe has been ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250